Microvessel density in prostatic hyperplasia

被引:39
作者
Foley, SJ
Bailey, DM
机构
[1] Royal Bournemouth Hosp, Dept Urol, Bournemouth, Dorset, England
[2] Wycombe Gen Hosp, Dept Cellular Pathol, High Wycombe, Bucks, England
关键词
benign prostatic hyperplasia; microvessel density; haematuria;
D O I
10.1046/j.1464-410x.2000.00322.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To examine the prostates from patients with haematuria associated with benign prostatic hyperplasia (BPH) to determine their microvascular anatomy and thus assess histopathological differences in patients with significant haematuria. Patients and methods Prospectively, 11 patients with EPH and haematuria (mean age 70 years) and 19 control patients with BPH alone (mean age 72 years) were identified. Neither group had received hormone manipulation or had been catheterized. The suburothelial compartment of the prostatic urethra in subsequent specimens from transurethral resection was examined using factor VIII/CD-34 immunohistochemistry. The microvessel density (MVD) was calculated by counting vascular cross-sectional profiles within a 0.81-mm(2) grid. The pathologist studying the specimens was unaware of the patients' symptoms. Results The median (range) MVD in the haematuria group was 64 (28-137) and in the controls was 27 (14-39) (P<0.001), Conclusion The MVD was significantly greater in the patients with haematuria, suggesting that suburothelial microvessel proliferation may play an important role in mediating haematuria associated with BPH. This is the first time that a difference has been shown at the cellular level in patients with haematuria and could form an important foundation for subsequent research.
引用
收藏
页码:70 / 73
页数:4
相关论文
共 23 条
[1]   CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy [J].
Bettencourt, MC ;
Bauer, JJ ;
Sesterhenn, IA ;
Connelly, RR ;
Moul, JW .
JOURNAL OF UROLOGY, 1998, 160 (02) :459-465
[2]  
Bostwick D G, 1998, Semin Urol Oncol, V16, P118
[3]  
Brawer MK, 1996, CANCER, V78, P345, DOI 10.1002/(SICI)1097-0142(19960715)78:2<345::AID-CNCR25>3.0.CO
[4]  
2-V
[5]   Advances in angiogenesis research: Relevance to urological oncology [J].
Campbell, SC .
JOURNAL OF UROLOGY, 1997, 158 (05) :1663-1674
[6]   Resistance to apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation [J].
Cardillo, M ;
Berchem, G ;
Tarkington, MA ;
Krajewski, S ;
Krajewski, M ;
Reed, JC ;
Tehan, T ;
Ortega, L ;
Lage, J ;
Gelmann, EP .
JOURNAL OF UROLOGY, 1997, 158 (01) :212-216
[7]   ANGIOGENESIS AS A PROGNOSTIC MARKER IN EARLY HEAD AND NECK-CANCER [J].
DRAY, TG ;
HARDIN, NJ ;
SOFFERMAN, RA .
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 1995, 104 (09) :724-729
[8]   Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: Lack of significance for microvessel density analysis [J].
Gettman, MT ;
Bergstralh, EJ ;
Blute, M ;
Zincke, H ;
Bostwick, DG .
UROLOGY, 1998, 51 (01) :79-85
[9]  
HASAN ST, 1994, BR J UROL, V73, P151
[10]   Haematuria associated with BPH - Natural history and a new treatment option [J].
Kashif, KM ;
Foley, SJ ;
Basketter, V ;
Holmes, SAV .
PROSTATE CANCER AND PROSTATIC DISEASES, 1998, 1 (03) :154-156